The following abstracts represent the presentations given at IWWM-10 (NYC-2018), Session 10: Clinical Trials Updates in WM: Novel Agents and Trials in Progress
Session Chair: Meletios Dimopoulos (Greece)
Phase II Study of the BTK-inhibitor Acalabrutinib in previously-treated WM patients R. Furman (USA)
Phase II Study of the BTK-inhibitor Zanubrutinib in symptomatic WM patients C. Tam (Australia)
Phase III Study of Zanubrutinib vs. Ibrutinib in symptomatic WM patients J. Huang (USA)
Phase II Study of the BCL2-inhibitor Venetoclax in previously treated WM patients J. Castillo (USA)
Phase I/II Study of the CXCR4-inhibitor Ulocuplomab plus ibrutinib in symptomatic WM patients S. Treon (USA)
Phase II Study of the CD38-antibody Daratumumab in previously treated WM patients J. Castillo (USA)